OnKure Therapeutics (OKUR) 8-K Reneo Pharmaceuticals Reports Second Quarter 2021 Financial Results

Exhibit 99.1

Reneo Pharmaceuticals Reports Second Quarter 2021 Financial Results

First patient dosed in STRIDE study of REN001 in primary mitochondrial myopathies

Irvine, August 11, 2021 -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic, mitochondrial diseases, today reported financial results for the quarter ended June 30, 2021 and provided an update on its clinical programs.

“The second quarter of 2021 was highly productive for the Reneo team as we launched the international STRIDE study, completed enrollment of the McArdle disease study, and made substantial progress in our long-chain fatty acid oxidation disorders studies,” said Gregory J. Flesher, President and Chief Executive Officer of Reneo Pharmaceuticals. “In addition, we completed our initial public offering, and now have sufficient capital to fund operations through all of our planned near-term clinical milestones.”

Key Operational Highlights

● Dosed the first patient in the STRIDE study, a global, randomized, double-blind, placebo-controlled Phase 2b clinical trial of REN001 in patients with primary mitochondrial myopathies (PMM)

● Completed enrollment of study REN001-103, an open-label Phase 1b clinical trial in patients with glycogen storage disease type V (McArdle disease)

● Dosed 20 patients to date in study REN001-102, an open-label Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorder (LC-FAOD)

● Enrolled 18 patients to date in the FORWARD study, an observational clinical trial in patients with LC-FAOD

● The company was added to the Russell 2000^® and Russell 3000^® Indices

Financial Results for the Three Months Ended June 30, 2021

The company reported a net loss of $9.2 million, or $0.43 per share, for the three months ended June 30, 2021, compared to a net loss of $3.7 million, or $1.82 per share, for the same period in 2020. The company had $167.3 million in cash, cash equivalents and short-term investments as of June 30, 2021.

Research and development expenses for the three months ended June 30, 2021 were $6.3 million, compared to $2.8 million for the three months ended June 30, 2020. This increase of $3.5 million in research and development expenses was primarily due to an increase of $2.3 million related to clinical trial costs associated with the launch of our STRIDE and FORWARD studies as well as the restart of our Phase 1b clinical trials of LC-FAOD and McArdle disease and $0.4 million in employee and personnel related costs due to additional headcount required to support our clinical and CMC programs, offset by a $0.7 million decrease in expense related to completion of preclinical studies. The net increase was further offset by a reduction in credits to research and development expenses related to tax rebates paid in cash by the United Kingdom government, as the Company did not receive a credit in the three months ended June 30, 2021 but received a $1.5 million tax rebate in the three months ended June 30, 2020.

1

General and administrative expenses for the three months ended June 30, 2021, were $2.9 million, compared to $0.9 million during the three months ended June 30, 2020. This increase of $2.0 million was primarily attributable to an increase of $1.0 million in employee and personnel related expenses, an increase of $0.4 million of directors and officers insurance premiums following our IPO, an increase of $0.4 million of compensation charge related to a stock-based performance award, and a net increase of $0.2 million of various other expense items.

Anticipated Upcoming Milestones

● Results from the Phase 1b clinical trial in McArdle disease (1Q 2022)

● Results from the Phase 1b clinical trial in LC-FAOD (1H 2022)

● Results from the FORWARD study (2H 2022)

Corporate Access Events

● Citi’s 16^th Annual BioPharma Conference, September 8-10, 2021

● H.C. Wainwright 23^rd Annual Global Investment Conference, September 13-15, 2021

● Baird Global Healthcare Conference, September 14-15, 2021

● SVB Leerink Neuromuscular, Rare Diseases & Genetic Medicines Event, September 22-23, 2021

● Cantor Global Healthcare Conference, September 27-30, 2021

About Reneo Pharmaceuticals

Reneo is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Reneo is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes. REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation, and may increase production of new mitochondria.

About REN001

REN001 is a potent and selective peroxisome proliferator-activated receptor delta (PPARδ) agonist currently in clinical development for three rare genetic mitochondrial diseases that typically present with myopathy and have high unmet medical needs: primary mitochondrial myopathies (PMM), long-chain fatty acid oxidation disorders (LC-FAOD), and glycogen storage disorder type V (McArdle disease). For more information on REN001 clinical trials, please see clinicaltrials.gov.

About PMM

PMM are a group of disorders that affect roughly 1 in 5,000 people worldwide. PMM are caused by genetic mutations in the mitochondrial or nuclear DNA that reduce the ability of mitochondria to produce energy from nutrient sources. This energy deficit particularly affects tissues and organs with high energy demand such as muscle, brain, and heart. The symptoms of PMM include muscle weakness or exercise intolerance, movement disorder, deafness, blindness, and droopy eyelids among others. The prognosis for these disorders ranges in severity from progressive weakness to death.

About STRIDE

STRIDE is a global, randomized, double-blind, placebo-controlled Phase 2b clinical trial designed to assess the efficacy and safety of 100 mg REN001 administered orally once daily to patients with PMM. Approximately 200 adult PMM patients with alterations in mitochondrial DNA and a history of myopathy are expected to be enrolled into STRIDE. The primary efficacy endpoint of the trial is the change from baseline in the distance walked during a 12-minute walk test after 24 weeks of treatment. Secondary efficacy endpoints include changes

2

from baseline in the Modified Fatigue Impact Scale (MFIS), Patient Global Impression of Change scale (PGIC), and other patient-reported outcomes.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the results, conduct, progress and timing of Reneo’s clinical trials, the regulatory approval path for REN001 and uses of capital. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “plans,” “will,” “believes,” “anticipates,” “expects,” “intends,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Reneo’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Reneo’s business in general, and the other risks described in Reneo’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Reneo undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

3

RENEO PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and par value data)

	JUNE 30,		DECEMBER 31,
	2021		2020
Assets	(unaudited)
Current assets:
Cash and cash equivalents	$	140,368	$	53,613
Short-term investments		26,963		—
Prepaid expenses and other current assets		3,810		1,412
Total current assets		171,141		55,025
Property and equipment, net		85		69
Other non-current assets		78		127
Total assets	$	171,304	$	55,221
Liabilities, convertible preferred stock and stockholders’ equity (deficit)
Current liabilities:
Accounts payable	$	434	$	908
Accrued expenses		2,902		3,672
Total current liabilities		3,336		4,580
Deferred rent		54		36
Performance Award		363		—
Total liabilities		3,753		4,616
Commitments and contingencies
Series A convertible preferred stock, $0.0001 par value; zero and 24,302,472 shares authorized at June 30, 2021 and December 31, 2020, respectively; zero and 24,302,472 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively; liquidation preference of $0 and $49,127 at June 30, 2021 and December 31, 2020, respectively		—		45,652
Series B convertible preferred stock, $0.0001 par value; zero and 46,881,028 shares authorized at June 30, 2021 and December 31, 2020, respectively; zero and 23,440,514 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively; liquidation preference of $0 and $47,385 as of June 30, 2021 and December 31, 2020, respectively		—		47,068
Stockholders’ equity (deficit):
Preferred stock, $0.0001 par value, 10,000,000 and zero shares authorized at June 30, 2021 and December 31, 2020, respectively; zero shares issued and outstanding as of June 30, 2021 and December 31, 2020		—		—
Common stock, $0.0001 par value; 200,000,000 and 105,000,000 shares authorized at June 30, 2021 and December 31, 2020, respectively; 24,305,822 and 24,288,699 shares issued and outstanding at June 30, 2021, respectively and 2,053,070 shares issued and outstanding at December 31, 2020		3		—
Additional paid-in capital		228,929		2,843
Accumulated deficit		(61,386)		(44,958)
Accumulated other comprehensive income		5		—
Total stockholders’ equity (deficit)		167,551		(42,115)
Total liabilities, convertible preferred stock and stockholders’ equity (deficit)	$	171,304	$	55,221

4

RENEO PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

(in thousands, except share and per share data)

	THREE MONTHS ENDED JUNE 30,				SIX MONTHS ENDED JUNE 30,
	2021		2020		2021		2020
Operating expenses:
Research and development	$	6,279	$	2,817	$	11,751	$	6,395
General and administrative		2,949		882		4,691		1,807
Total operating expenses		9,228		3,699		16,442		8,202
Loss from operations		(9,228)		(3,699)		(16,442)		(8,202)
Other income		12		12		14		84
Net loss		(9,216)		(3,687)		(16,428)		(8,118)
Unrealized gain (loss) on short-term investments		5		(6)		5		1
Comprehensive loss	$	(9,211)	$	(3,693)	$	(16,423)	$	(8,117)
Net loss per share attributable to common stockholders, basic and diluted	$	(0.43)	$	(1.82)	$	(1.40)	$	(4.02)
Weighted-average shares used in computing net loss per share, basic and diluted		21,364,369		2,022,174		11,770,948		2,018,602

5

RENEO PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(in thousands)

	SIX MONTHS ENDED
	JUNE 30,
	2021		2020
Cash flows from operating activities
Net loss	$	(16,428)	$	(8,118)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		20		18
Amortization/accretion on short-term investments		33		(16)
Changes in the fair value of Performance Award		363		—
Stock-based compensation		1,325		180
Changes in operating assets and liabilities:
Accounts payable, accrued expenses and other		(1,164)		934
Prepaid expenses and other assets		(2,457)		(380)
Deferred rent		18		(2)
Net cash used in operating activities		(18,290)		(7,384)
Cash flows from investing activities
Purchases of property and equipment		(31)		(1)
Purchase of available-for-sale short-term investments		(26,989)		—
Proceeds from maturities of available-for-sale short-term investments		—		6,200
Net cash (used in) provided by investing activities		(27,020)		6,199
Cash flows from financing activities
Proceeds from issuance of Series B convertible preferred stock, net of issuance costs		47,239		—
Proceeds from initial public offering, net of offering costs		84,639		—
Proceeds from exercise of stock options		187		26
Net cash provided by financing activities		132,065		26
Net increase (decrease) in cash and cash equivalents		86,755		(1,159)
Cash and cash equivalents, beginning of period		53,613		17,501
Cash and cash equivalents, end of period	$	140,368	$	16,342
Supplemental cash flow information:
Property and equipment in accounts payable	$	10	$	—
Costs incurred in connection with initial public offering included in accrued expenses	$	30	$	—

Contacts:

Joyce Allaire Managing Director
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com ​ Vinny Jindal
Chief Financial Officer Reneo Pharmaceuticals, Inc. vjindal@reneopharma.com

6